Program to up access to combo malaria therapy successful

November 1, 2012 in Diseases, Conditions, Syndromes

Program to up access to combo malaria therapy successful

Implementation of a series of national-scale pilot programs designed to increase the access and use of quality-assured artemisinin-based combination therapies (QAACTs) for malaria by the Affordable Medicines Facility-malaria has improved the availability, price, and market share of QAACTs, according to a study published online Oct. 31 in The Lancet.

(HealthDay)—Implementation of a series of national-scale pilot programs designed to increase the access and use of quality-assured artemisinin-based combination therapies (QAACTs) for malaria by the Affordable Medicines Facility-malaria (AMFm) has improved the availability, price, and market share of QAACTs, according to a study published online Oct. 31 in The Lancet.

Sarah Tougher, M.D.E., from the London School of Hygiene and Tropical Medicine, and colleagues conducted nationally representative baseline and end point surveys of public and private sector outlets that stock antimalarial therapies to examine the effect of AMFm on QAACT price, availability, and six to 15 months after delivery of subsidized artemisinin-based combination therapies in seven countries (Ghana, Kenya, Madagascar, Niger, Nigeria, Uganda, and Tanzania [including Zanzibar]).

The researchers found that, with the exception of Niger and Madagascar, in all other pilots there were large increases in the availability of QAACT and in market share. These were mainly driven by changes in the private for-profit sector. In six pilots, large falls were seen in the median price for QAACTs per adult equivalent dose in the private for-profit sector. In Nigeria and Zanzibar, where the market share of oral artemisinin monotherapies was more than 5 percent at baseline, a decrease was observed.

"In summary, our evaluation has shown that subsidies applied to manufacturer price, when partnered with supporting interventions such as communications campaigns, can be an effective mechanism to rapidly improve the availability, price, and market share of QAACTs, particularly in the private for-," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Journal reference: The Lancet search and more info website

Copyright © 2012 HealthDay. All rights reserved.

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Researchers find genetic risk factor for pulmonary fibrosis

A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibros ...

Diseases, Conditions, Syndromes created 8 hours ago | popularity not rated yet | comments 0

Biomarkers discovered for inflammatory bowel disease

Using the Department of Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers have identified a number of biomarkers for inflammatory bowel disease (IBD), which could help with earlier diagnosis and ...

Diseases, Conditions, Syndromes created 8 hours ago | popularity 5 / 5 (1) | comments 0

CDC says high number of public pools contain microbes

(HealthDay)—Three-quarters of public schools in the metro Atlanta area contain microbes, including bacteria indicating the presence of fecal matter, according to research published in the May 17 issue of ...

Diseases, Conditions, Syndromes created 9 hours ago | popularity not rated yet | comments 0

Study examines outbreak of spinal infections in Michigan

(HealthDay)—Factors such as increased case finding may explain why Michigan had half of the total spinal infections associated with contaminated methylprednisolone acetate in the recent fungal meningitis ...

Diseases, Conditions, Syndromes created 9 hours ago | popularity not rated yet | comments 0

World not ready for mass flu outbreak, WHO says

The world is unprepared for a massive virus outbreak, the deputy chief of the World Health Organization warned Tuesday, amid fears that H7N9 bird flu striking China could morph into a form that spreads easily among people.

Diseases, Conditions, Syndromes created 10 hours ago | popularity not rated yet | comments 0


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.